Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.43 |
| ▸ | MAOB known ✓ | P27338 | 4/20 | 0.41 |
| ▸ | MAOA known ✓ | P21397 | 2/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.41 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | ELANE | P08246 | 1/20 | 0.58 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999563 | 0.98 | FAAH (0.60) | FAAHPRSS1PRSS2ELANEPRTN3 | |
| SCHEMBL3900282 | 0.80 | F2 (0.64) | FAAHPRSS1PRSS2ELANEPRTN3 | |
| SCHEMBL10760737 | 0.78 | ALDH1A1 (0.50) | FAAHPRSS1PRSS2ELANEPRTN3 | |
| SCHEMBL1449580 | 0.78 | TSHR (0.50) | RECQLTSHRCYP3A4TDP1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1053300 | 0.77 | FAAH (0.58) | FAAHPRSS1PRSS2ELANEPRTN3 | |
| SCHEMBL9421733 | 0.76 | FAAH (0.62) | FAAHPRSS1PRSS2ELANEPRTN3 | |
| Phenylmethylsulfonylfluoride SCHEMBL4869292 | 0.76 | PRSS1 (0.95) | FAAHPRSS1PRSS2ELANEPRTN3 | |
| SCHEMBL2984207 | 0.76 | CA1 (0.62) | RECQLTSHRCYP3A4TDP1ALDH1A1 | |
| SCHEMBL514597 | 0.76 | RECQL (0.48) | RECQLTSHRCYP3A4TDP1ALDH1A1 | |
| SCHEMBL1335821 | 0.74 | TSHR (0.50) | RECQLTSHRCYP3A4TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365076-B2 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-04-29 | — | — | US | claimed |
| EP-1687288-B1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH CORP (US) | 2008-01-16 | — | — | EP | claimed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| EP-4135660-A1 | COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-111068062-B | Methods of treating interleukin-6 related diseases | 中外制药株式会社 | 2022-07-19 | — | — | CN | disclosed |
| WO-2021211808-A1 | COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS | ATOSSA THERAPEUTICS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| CN-105617387-B | Methods of treating interleukin-6 related diseases | 中外制药株式会社 | 2021-09-14 | — | — | CN | disclosed |
| CN-111068062-A | Methods of treating interleukin-6 related diseases | 中外制药株式会社 | 2020-04-28 | — | — | CN | disclosed |
| US-9993425-B2 | Compositions for intranasal delivery of human insulin and uses thereof | MARINA BIOTECH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2226632-B1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8450070-B2 | Method for screening of cell-protecting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-0521156-B1 | DNA CODING FOR GRANULOCYTIC COLONY STIMULATING FACTOR RECEPTOR | OSAKA BIOSCIENCE INST (JP) | 1999-07-07 | — | — | EP | disclosed |
| US-5776446-A | GENES OF POLYPEPTIDES FOR GENETIC ENGINEERING | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-07-07 | — | — | US | disclosed |
| US-5574136-A | DNA encoding granulocyte colony-stimulating factor receptor and protein thereof | OSAKA BIOSCIENCE INSTITUTE (JP) | 1996-11-12 | — | — | US | disclosed |
| EP-0675200-A1 | A FAS ligand, a fragment thereof and DNA encoding the same | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1995-10-04 | — | — | EP | disclosed |
| US-5403725-A | Human T-cell hybridomas are incubated in medium of phorbol myristate acetate and/or concanavalin A, fractionated by sucrose density gradient centrifugation | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1995-04-04 | — | — | US | disclosed |
| US-5182195-A | Respiratory-deficient transformant | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-01-26 | — | — | US | disclosed |
| EP-0521156-A1 | DNA CODING FOR GRANULOCYTIC COLONY STIMULATING FACTOR RECEPTOR | OSAKA BIOSCIENCE INSTITUTE (JP) | 1993-01-07 | — | — | EP | disclosed |
| EP-0230781-B1 | LYMPHOTOXIN GENE, METHOD FOR ITS PRODUCTION, AND LYMPHOTOXIN | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-07-22 | — | — | EP | disclosed |
| EP-0230781-A2 | Lymphotoxin gene, method for its production, and lymphotoxin | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | GAA 675/4885MAOB 12/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.